Treatment
Belimumab clinical trials
We’re tracking 21 recruiting studies that include Belimumab, each written for real people, not researchers, below.
Recruiting studies
- NCT03949855RecruitingPhase 2
Belimumab plus rituximab for primary membranous nephropathy
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
Birmingham, AlabamaAges 18–75 - NCT04629144RecruitingPhase 2
Belimumab for active cryoglobulinemia vasculitis after rituximab
This Phase 2 study tests belimumab (or a placebo) to see if it improves safety and disease control in adults with active cryoglobulinemia vasculitis. You may be eligible if you have had rituximab induction treatment shortly before joining, and your illness is still active.
BloisAges 18 years+ - NCT07611214RecruitingPhase 4
LUPKYNIS Combined With Immune-Targeting Drugs for Lupus Kidney Disease
This study tests whether adding LUPKYNIS (a drug that protects the kidney) to one of three immune-system medications helps people with lupus nephritis (lupus affecting the kidneys). The goal is to reduce protein in urine and protect kidney function.
La Mesa, CaliforniaAges 18–75 - NCT03543839RecruitingPhase 4
Belimumab for early lupus activity in the first two years
This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.
Manhasset, New YorkAges 18 years+ - NCT03844061RecruitingPhase 2
Belimumab plus rituximab for early diffuse scleroderma skin disease
This Phase 2 study tests whether combining belimumab and rituximab can improve skin thickening in people with early diffuse cutaneous systemic sclerosis (dcSSc). It may help slow the disease process and improve skin symptoms, but it also requires screening for immune and infection risks.
New York, New YorkAges 18–80 - NCT04097561RecruitingPhase 1
Belimumab safety study for low CD4 counts and autoantibodies
This Phase 1 study tests how safe belimumab is for people with idiopathic CD4 lymphopenia (low protective white blood cells) and signs of autoantibodies. It aims to learn whether the treatment is tolerable and could be a future option for people with this immune condition.
Bethesda, MarylandAges 18–70 - NCT05338190RecruitingPhase 3
Belimumab added to rituximab for chronic immune thrombocytopenia
This Phase 3 study tests whether adding an injection called belimumab (or a placebo) to rituximab works better and is safe for adults with long-lasting immune thrombocytopenia (ITP). You may be eligible if your platelet counts stay low despite prior steroid and/or IVIG treatment and if infections, vaccines, and other health conditions meet the study rules.
CréteilAges 18 years+ - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Phoenix, ArizonaAges 18 years+ - NCT06381453RecruitingPhase 2
Belimumab for autoimmune hepatitis
This trial tests a drug called belimumab for people with autoimmune hepatitis that is not well controlled. It aims to see if adding belimumab to your current treatment can help reduce liver inflammation.
Calgary, AlbertaAges 18–80 - NCT06410833RecruitingPhase 4
Combination therapy for resistant Sjögren's in children
This trial tests a combination of two medicines, rituximab then belimumab, for children and teens with Sjögren's syndrome that hasn't improved with other treatments. The goal is to see if this two-step approach can better control symptoms like joint pain, skin rashes, and blood problems.
Beijing, Beijing MunicipalityAges 5–18 - NCT06411249RecruitingPhase 4
Belimumab for people with early lupus
This study tests whether a medicine called belimumab (Benlysta) works better for people diagnosed with lupus in the last 2 years. It aims to slow down the disease before it causes lasting organ damage.
Anniston, AlabamaAges 18 years+ - NCT06572384RecruitingPhase 3
Belimumab for lung scarring in autoimmune disease
This study tests whether a drug called belimumab can help people with lung scarring caused by certain autoimmune diseases (like rheumatoid arthritis or lupus). If you have active lung disease despite standard therapy, this trial may be an option.
Los Angeles, CaliforniaAges 18 years+ - NCT06716606RecruitingPhase 3
Long-term safety of belimumab for lung disease in scleroderma and other connective tissue diseases
This study tests the long-term safety and effectiveness of belimumab for people with lung scarring caused by scleroderma or other connective tissue diseases. It is for patients who already completed a one-year study with belimumab and were not considered treatment failures.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06747312RecruitingPhase 2
Belimumab for antiphospholipid syndrome (APS)
This study tests if belimumab lowers harmful antibody levels in people with antiphospholipid syndrome (APS), a condition that increases blood clot risk. It may help those who are already on a stable APS treatment plan.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07340463RecruitingPhase 2
Biologics vs standard therapy for lupus kidney disease
This trial tests two biologic drugs (belimumab or telitacicept) compared to a standard treatment (mycophenolate mofetil) for people with active lupus nephritis. The goal is to see if biologics work better at controlling kidney inflammation over 6 months.
Nanjing, JiangsuAges 14–65 - NCT06857214RecruitingPhase 1
GNC-038 antibody study for moderate to severe lupus
This trial tests a new antibody treatment, GNC-038, for people with moderate to severe lupus. It aims to see if it's safe and effective. You must have stable lupus treatment and active B cells in your blood.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07138898RecruitingPhase 2
Managing immune medications for shoulder replacement in rheumatology patients
This trial tests two ways of managing your immunosuppressant medication around the time of shoulder replacement surgery. The goal is to see if one approach leads to fewer infections while still controlling your rheumatic disease.
New York, New YorkAges 18 years+ - NCT06576271RecruitingPhase 1
Testing a new drug for lupus and related lung disease
This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.
Scottsdale, ArizonaAges 18–65 - NCT07056621Recruiting
How belimumab changes lupus over time
This study looks at how the drug belimumab affects the long-term course of lupus. It compares patients who receive belimumab to similar patients who do not, to see if it helps control disease activity over time.
Athens, AtticaAges 18 years+ - NCT07225387RecruitingPhase 4
Belimumab and voclosporin for lupus kidney disease
This study tests whether combining two medications, belimumab and voclosporin, is safe and effective for treating a specific type of lupus that affects the kidneys (lupus nephritis). It may help people with active kidney inflammation who need better control of their disease.
Glendale, ArizonaAges 18–80 - NCT06527872Recruiting
Study of belimumab for lupus kidney disease in real life
This study looks at how well belimumab (Benlysta) works in real-world settings for adults with lupus nephritis (kidney inflammation caused by lupus). If you started belimumab in the past 6–24 months, the researchers will review your medical records to see how your kidney health has changed.
Baltimore, MarylandAges 18 years+
What Belimumab is being studied for
Conditions with recruiting Belimumab studies.
Common questions
- Are there clinical trials studying Belimumab?
- Yes. Clin2 currently lists 21 recruiting studies that include Belimumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Belimumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Belimumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Belimumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.